Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5086099
Max Phase: Preclinical
Molecular Formula: C41H49N7O8S
Molecular Weight: 799.95
Molecule Type: Unknown
Associated Items:
ID: ALA5086099
Max Phase: Preclinical
Molecular Formula: C41H49N7O8S
Molecular Weight: 799.95
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCC(=O)Nc2ccc(C(=O)Nc3ccccc3N)cc2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C41H49N7O8S/c1-25-36(57-24-44-25)27-11-9-26(10-12-27)20-43-39(53)33-19-30(49)21-48(33)40(54)37(41(2,3)4)47-35(51)23-56-18-17-55-22-34(50)45-29-15-13-28(14-16-29)38(52)46-32-8-6-5-7-31(32)42/h5-16,24,30,33,37,49H,17-23,42H2,1-4H3,(H,43,53)(H,45,50)(H,46,52)(H,47,51)/t30-,33+,37-/m1/s1
Standard InChI Key: LDFNYUSMNVVOAO-FHRXIHKVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 799.95 | Molecular Weight (Monoisotopic): 799.3363 | AlogP: 3.73 | #Rotatable Bonds: 16 |
Polar Surface Area: 214.31 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 15 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.91 | CX Basic pKa: 3.24 | CX LogP: 1.62 | CX LogD: 1.62 |
Aromatic Rings: 4 | Heavy Atoms: 57 | QED Weighted: 0.07 | Np Likeness Score: -0.92 |
1. Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT.. (2022) Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells., 65 (7.0): [PMID:35293758] [10.1021/acs.jmedchem.1c02179] |
Source(1):